Search
Stallimycin
go.drugbank.com/drugs/DB20261ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Stallimycin is a antibiotic, produced by Streptomyces strain. Stallimycin has a monoisotopic molecular weight of 481.22 Da.
Bluensomycin
go.drugbank.com/drugs/DB20923ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Bluensomycin is a antibiotic, produced by Streptomyces strain. Bluensomycin has a monoisotopic molecular weight of 585.25 Da.
Steffimycin
go.drugbank.com/drugs/DB19922ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Steffimycin is a antibiotic, produced by Streptomyces strain. Steffimycin has a monoisotopic molecular weight of 574.17 Da.
Anthelmycin
go.drugbank.com/drugs/DB20238ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Anthelmycin is a antibiotic, produced by Streptomyces strain. Anthelmycin has a monoisotopic molecular weight of 583.23 Da.
Lydimycin
go.drugbank.com/drugs/DB21235ExperimentalThe usage of the INN stem '-mycin' in the name indicates that Lydimycin is a antibiotic, produced by Streptomyces strain. Lydimycin has a monoisotopic molecular weight of 242.07 Da.
SRP-9005
go.drugbank.com/drugs/DB17958InvestigationalDeveloped by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]
ARC183
go.drugbank.com/drugs/DB05124ExperimentalARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid
MW33
go.drugbank.com/drugs/DB16358ExperimentalMW33 is a recombinant fully human antibody to SARS-CoV-2. … [L27411] This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
CX157
go.drugbank.com/drugs/DB05205InvestigationalCX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous
MP4
go.drugbank.com/drugs/DB05313InvestigationalMP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.